Joseph A. Ware

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Debashis Sarker, Joo Ern Ang, Richard D. Baird et al. · Clinical Cancer Research · 2014 · 360 citations · Full text

Medicine, Oncology, Pharmacology +15

Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)

John A. Flygare, Maureen H. Beresini, Nageshwar Budha et al. · Journal of Medicinal Chemistry · 2012 · 248 citations · Full text

Medicine, Oncology, Pharmacology +17

Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug–Drug Interaction Potential for Molecular Targeted Agents in Clinical Development

Gillian S. Smelick, Timothy P. Heffron, Laura Chu et al. · Molecular Pharmaceutics · 2013 · 188 citations

Medicine, Oncology, Pharmacology +14

Breast Cancer Resistance Protein (Bcrp/abcg2) Is a Major Determinant of Sulfasalazine Absorption and Elimination in the Mouse

Hani Zaher, Anis A. Khan, Joe Palandra et al. · Molecular Pharmaceutics · 2006 · 160 citations

Medicine, Pharmacokinetics, Pharmacology +11

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

Dejan Juric, Ian E. Krop, Ramesh K. Ramanathan et al. · Cancer Discovery · 2017 · 160 citations

Medicine, Oncology, Pharmacology +15